Troy Edward Wilson
CIK 1589597 · President and CEO · last filed 2026-09-16
Troy Edward Wilson is a President and CEO who has filed 80 SEC Form 4 insider transactions across 5 companies since 2013. The most recent filing shows the insider sold $45.5K of PBYI on Sep 16, 2026. Across all open-market trades the lifetime net is −$22.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KURA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
4930 DIRECTORS PLACE, SUITE 500
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PBYI | Director | 55,150 | $10.48 | $578.0K | -$959.2K | 22 | 2026-09-16 |
| KURA | President and CEO | 914,650 | $9.76 | $8.92M | -$15.84M | 32 | 2026-08-24 |
| Avidity Biosciences, Inc. (RNAM) Delisted | Director | 0 | — | — | $0 | 1 | 2026-02-27 |
| RNA | Director | 97,636 | $8.23 | $803.5K | -$5.75M | 10 | 2025-09-09 |
| Zosano Pharma Corp (ZSAN) Delisted | Director | 4 | $0.56 | $2 | $0 | 5 | 2019-07-18 |
Recent Filings
80 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-16 | PBYI | Sell (S) | −5,000 | -$45.5K | EDGAR |
| 2026-09-14 | PBYI | Notice (144) | −5,000 | -$45.5K | EDGAR |
| 2026-08-24 | KURA | Buy (P) | +100,000 | $1.24M | EDGAR |
| 2026-08-17 | KURA | Buy (P) | +100,000 | $1.11M | EDGAR |
| 2026-06-15 | PBYI | Mixed | +16,200 | -$77.7K | EDGAR |
| 2026-06-12 | PBYI | Notice (144) | −10,800 | -$78.4K | EDGAR |
| 2026-03-25 | KURA | Exer (M) | +6,103 | $37.5K | EDGAR |
| 2026-03-02 | — | Grant (A) | — | $0 | |
| 2026-02-27 | Avidity Biosciences, Inc. (RNAM) Delisted | Disp (D) | −78,802 | $0 | EDGAR |
| 2026-01-06 | KURA | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.